Repligen (NASDAQ:RGEN) Stock Price Down 4.2%

Repligen Co. (NASDAQ:RGEN) shares fell 4.2% on Monday . The stock traded as low as $308.67 and last traded at $309.71. 1,289 shares changed hands during mid-day trading, a decline of 100% from the average session volume of 384,809 shares. The stock had previously closed at $323.26.

Several brokerages recently weighed in on RGEN. KeyCorp lifted their price objective on Repligen from $255.00 to $335.00 and gave the stock an “overweight” rating in a report on Friday, September 17th. Stephens lifted their target price on Repligen from $255.00 to $290.00 and gave the company an “overweight” rating in a report on Friday, August 20th. Finally, Craig Hallum lifted their target price on Repligen from $258.00 to $368.00 and gave the company a “buy” rating in a report on Monday. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Repligen has a consensus rating of “Buy” and an average target price of $280.50.

The company has a market cap of $16.60 billion, a PE ratio of 169.32 and a beta of 0.90. The company has a fifty day moving average price of $266.43 and a 200 day moving average price of $220.21.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Monday, July 26th. The biotechnology company reported $0.79 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.52 by $0.27. Repligen had a return on equity of 9.21% and a net margin of 19.65%. The company had revenue of $162.96 million during the quarter, compared to analyst estimates of $144.24 million. During the same quarter in the previous year, the firm earned $0.42 earnings per share. Repligen’s revenue was up 86.3% on a year-over-year basis. As a group, sell-side analysts expect that Repligen Co. will post 2.76 EPS for the current fiscal year.

In other Repligen news, Director Karen A. Dawes sold 4,585 shares of the business’s stock in a transaction that occurred on Tuesday, July 20th. The stock was sold at an average price of $202.09, for a total value of $926,582.65. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Anthony Hunt sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, September 9th. The shares were sold at an average price of $294.75, for a total value of $7,368,750.00. Following the completion of the sale, the chief executive officer now owns 214,495 shares of the company’s stock, valued at approximately $63,222,401.25. The disclosure for this sale can be found here. Insiders have sold 52,154 shares of company stock valued at $14,144,680 in the last three months. 1.20% of the stock is owned by insiders.

Hedge funds have recently made changes to their positions in the business. RPg Family Wealth Advisory LLC bought a new stake in Repligen in the second quarter valued at approximately $27,000. Creative Financial Designs Inc. ADV raised its holdings in shares of Repligen by 50.0% during the second quarter. Creative Financial Designs Inc. ADV now owns 150 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 50 shares in the last quarter. Itau Unibanco Holding S.A. bought a new position in shares of Repligen during the second quarter valued at approximately $37,000. Rational Advisors LLC bought a new position in shares of Repligen during the second quarter valued at approximately $48,000. Finally, Huntington National Bank raised its holdings in shares of Repligen by 45.5% during the second quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 91 shares in the last quarter. Hedge funds and other institutional investors own 83.82% of the company’s stock.

About Repligen (NASDAQ:RGEN)

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration and OEM Products (Proteins). The Chromatography product line includes a number of products used in the downstream purification and quality control of biological drugs.

Featured Article: What is a Fiduciary?

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.